Literature DB >> 35042959

STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts.

Lidia Avalle1, Laura Raggi2,3, Emanuele Monteleone2,4, Aurora Savino2, Daniele Viavattene2, Luisa Statello2,5, Andrea Camperi2, Simona Aversano Stabile2, Vincenzo Salemme2, Niccolò De Marzo2, Francesca Marino2, Chiara Guglielmi2,6, Andrea Lobascio2, Cristina Zanini7, Marco Forni7, Danny Incarnato8,9, Paola Defilippi2, Salvatore Oliviero8, Valeria Poli10.   

Abstract

In the tumor microenvironment, Cancer Associated Fibroblasts (CAFs) become activated by cancer cells and increase their secretory activity to produce soluble factors that contribute to tumor cells proliferation, invasion and dissemination to distant organs. The pro-tumorigenic transcription factor STAT3 and its canonical inducer, the pro-inflammatory cytokine IL-6, act conjunctly in a positive feedback loop that maintains high levels of IL-6 secretion and STAT3 activation in both tumor and stromal cells. Here, we demonstrate that STAT3 is essential for the pro-tumorigenic functions of murine breast cancer CAFs both in vitro and in vivo, and identify a STAT3 signature significantly enriched for genes encoding for secreted proteins. Among these, ANGPTL4, MMP13 and STC-1 were functionally validated as STAT3-dependent mediators of CAF pro-tumorigenic functions by different approaches. Both in vitro and in vivo CAFs activities were moreover impaired by MMP13 inhibition, supporting the feasibility of a therapeutic approach based on inhibiting STAT3-induced CAF-secreted proteins. The clinical potential of such an approach is supported by the observation that an equivalent CAF-STAT3 signature in humans is expressed at high levels in breast cancer stromal cells and characterizes patients with a shorter disease specific survival, including those with basal-like disease.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35042959     DOI: 10.1038/s41388-021-02172-y

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  50 in total

1.  STAT3 can serve as a hit in the process of malignant transformation of primary cells.

Authors:  M Demaria; S Misale; C Giorgi; V Miano; A Camporeale; J Campisi; P Pinton; V Poli
Journal:  Cell Death Differ       Date:  2012-03-09       Impact factor: 15.828

Review 2.  Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

Authors:  Hua Yu; Marcin Kortylewski; Drew Pardoll
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

Review 3.  The biology and function of fibroblasts in cancer.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

4.  STAT3 in cancer: A double edged sword.

Authors:  Lidia Avalle; Annalisa Camporeale; Andrea Camperi; Valeria Poli
Journal:  Cytokine       Date:  2017-05-31       Impact factor: 3.861

Review 5.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 6.  Matrix metalloproteinases in tumor-host cell communication.

Authors:  Conor C Lynch; Lynn M Matrisian
Journal:  Differentiation       Date:  2002-12       Impact factor: 3.880

Review 7.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

Review 8.  STAT1 and STAT3 in tumorigenesis: A matter of balance.

Authors:  Lidia Avalle; Sara Pensa; Gabriella Regis; Francesco Novelli; Valeria Poli
Journal:  JAKSTAT       Date:  2012-04-01

9.  Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.

Authors:  Hanane Laklai; Yekaterina A Miroshnikova; Michael W Pickup; Eric A Collisson; Grace E Kim; Alex S Barrett; Ryan C Hill; Johnathon N Lakins; David D Schlaepfer; Janna K Mouw; Valerie S LeBleu; Nilotpal Roy; Sergey V Novitskiy; Julia S Johansen; Valeria Poli; Raghu Kalluri; Christine A Iacobuzio-Donahue; Laura D Wood; Matthias Hebrok; Kirk Hansen; Harold L Moses; Valerie M Weaver
Journal:  Nat Med       Date:  2016-04-18       Impact factor: 53.440

Review 10.  A framework for advancing our understanding of cancer-associated fibroblasts.

Authors:  Erik Sahai; Igor Astsaturov; Edna Cukierman; David G DeNardo; Mikala Egeblad; Ronald M Evans; Douglas Fearon; Florian R Greten; Sunil R Hingorani; Tony Hunter; Richard O Hynes; Rakesh K Jain; Tobias Janowitz; Claus Jorgensen; Alec C Kimmelman; Mikhail G Kolonin; Robert G Maki; R Scott Powers; Ellen Puré; Daniel C Ramirez; Ruth Scherz-Shouval; Mara H Sherman; Sheila Stewart; Thea D Tlsty; David A Tuveson; Fiona M Watt; Valerie Weaver; Ashani T Weeraratna; Zena Werb
Journal:  Nat Rev Cancer       Date:  2020-01-24       Impact factor: 60.716

View more
  4 in total

1.  Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development.

Authors:  Stephen F Madden; Mattia Cremona; Angela M Farrelly; Weng Hei Low; Jean McBryan
Journal:  Cancer Gene Ther       Date:  2022-10-20       Impact factor: 5.854

2.  DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer.

Authors:  Geoffrey Casas; Federico Perche; Patrick Midoux; Chantal Pichon; Jean-Marc Malinge
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-22       Impact factor: 10.183

Review 3.  Interleukin-6 at the Host-Tumor Interface: STAT3 in Biomolecular Condensates in Cancer Cells.

Authors:  Pravin B Sehgal
Journal:  Cells       Date:  2022-03-30       Impact factor: 6.600

4.  Bioinformatic analysis of cancer-associated fibroblast related gene signature as a predictive model in clinical outcomes and immune characteristics of gastric cancer.

Authors:  Jiehao Zhang; Nannan Zhang; Xin Fu; Weizhen Wang; Hui Liu; Michael J McKay; Pornngarm Dejkriengkraikul; Yongzhan Nie
Journal:  Ann Transl Med       Date:  2022-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.